Roche Point of Care delivers those solutions meeting the clinical need for quick and accurate test results delivered where needed, when needed; on the device, in the electronic healthcare record on a patient/ward monitor, to the clinician on the move and directly to the patient. A handheld diabetes management device includes a blood glucose measurement engine that measures a blood glucose level of a patient. The device includes a physical port that is exposed at an exterior of the device. The device includes a processing module that includes first, second, and third physical interfaces that are internal to the device.
Roche Diagnostics Operations Inc. At 7988 CENTERPOINT DRIVE BLDGY /300 INDIANAPOLIS IN 46256 US. Find their customers, contact information, and details on 8556 shipments. Roche Diagnostics develops innovative products and services that address the prevention, diagnosis, monitoring, screening and treatment of diseases. You appear to be using incognito/private browsing mode or an ad blocker, which may adversely affect your experience on the site. The report on Global Rapid Diagnostics Devices Market offers in-depth analysis on market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report include the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. For the forecast years.
DUBLIN--(BUSINESS WIRE)--The 'Immunochemistry Diagnostic Devices And Equipment Global Market Report 2020' report has been added to ResearchAndMarkets.com's offering.
The global immunochemistry diagnostic devices and equipment market was valued at about $16.7 billion in 2018 and is expected to grow to $19.24 billion at a CAGR of 3.6% through 2022.
The immunochemistry diagnostic devices and equipment market consists of sales of immunochemistry diagnostic devices and related services. Immunochemistry diagnostic devices and equipment are designed to diagnose diseases or conditions by studying the functions of the immune system through analyzing the nature of specific proteins, antigens, antibodies and their interaction.
An increase in the incidence of target diseases is a major driver for the immunochemistry diagnostic devices and equipment market. The incidence rate of diseases such as viral infections, cardiovascular diseases, cancer or hormonal disorders is increasing worldwide, mainly due to poor lifestyle choices. For example, according to the American Heart Association, cardiovascular disease is the leading global cause of death, accounting for over 17.6 million deaths per year in 2016. This number is expected to grow to over 23.6 million by 2030.
Stringent regulatory policies related to approval of immunoassay instruments and consumables is a major restraint for the immunochemistry diagnostic devices and equipment market. Immunochemistry devices and equipment manufacturers are required to obtain multiple and separate clearances from the Food and Drug Administration (FDA) for launching their products. The entire process of regulatory approval is time consuming, with a minimum of about 18-30 months required for approval of class III devices and around 6-9 months required for approval of class II devices.
Roche Diagnostics Port Devices Driver
Companies in the immunochemistry diagnostic devices and equipment market are increasingly investing in automated immunoassay systems. This is mainly because automation has led to an increase in capabilities of diagnostic devices in testing higher volumes of patient specimens. In addition, the development of various integrated clinical chemistry systems have immensely improved the efficiency of analytical phase of clinical chemistry laboratory testing, and led to further automation.
For example, ichroma-50 is an automatic immunoassay analyzer of Boditech Med Inc. that measures the concentration of targeted analyte in body fluids such as blood, urine, and other samples in few minutes, and reduces the labor cost and human error in the process.
Roche Diagnostics Port Devices Drivers
In the USA, the immunochemistry diagnostic devices and equipment market is regulated under the U.S. Food and Drug Administration (FDA), and all diagnostic laboratory tests are regulated by the clinical laboratory improvement amendments of 1988 (CLIA), which is administered by the centers for medicare & medicaid services (CMS). A CLIA/FDA compliant laboratory is required to file a PMA/510(k) for market approval of any immunochemistry device. Hence, the regulatory scenario related to immunochemistry diagnostic devices and equipment will keep a check on the companies that manufacture these devices and equipment.
Major players in the market are Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare Diagnostics, Diamond Diagnostics, and Dynex Technologies.
Other Companies Mentioned
- Grifols
- Hycor Biomedical
- Immunodiagnostic Systems
- Inova Diagnostics
- LabCorp
- Mindray
- Ortho Clinical Diagnostics
- Quest Diagnostics
- Randox Laboratories
- Sysmex
- ThermoFisher Scientific
- Tosoh Bioscience
- Danaher
- Johnson & Johnson
- Boditech Med Inc
- Beckman Coulter
- Bio-Rad Laboratories
- BioMerieux
- Carolina Liquid Chemistries Corporate
- DiaSorin
For more information about this report visit https://www.researchandmarkets.com/r/npnwaf
- Type of Event
- Event ID 43176
- Event Risk Class
- Event Initiated Date 2014-11-28
- Event Country
- Event Source HC
- Notes / Alerts Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada. - Extra notes in the data
- Reason There is a potential issue between the cobas it middleware system and customer laboratory information system (lis) when spaces are used in the sample id's. if the lis sends sample id with leading spaces to citm this id will be saved with spaces when an instrument sends results back to citm since the driver removes these spaces during the transmission therefore sample id not found or wrong sample id association may occur.